Business Context and Reporting Period
Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2007 (Q1 2007)
Filing Date: April 26, 2007
Alcon operates globally through two segments: Alcon United States and Alcon International. The company markets products in three categories: pharmaceuticals, surgical equipment/devices, and consumer eye care.
Key Financial Metrics
| Metric (in millions) | Q1 2007 | Q1 2006 |
|---|---|---|
| Sales (Revenue) | $1,322.7 | $1,157.1 |
| Gross Profit | $973.7 | $868.9 |
| Gross Margin | 73.6% | 75.1% |
| Operating Income | $403.1 | $342.4 |
| Net Earnings | $346.2 | $295.7 |
| Diluted EPS | $1.14 | $0.95 |
| Operating Cash Flow | $342.9 | $267.6 |
| Cash & Equivalents (End Period) | $1,496.2 | $1,547.9 |
| Total Debt | $957.6 | $981.3 |
| Net Cash Position | $538.6 | $507.9 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 14.3% year-over-year. Organic growth (constant currency) was 12.0%, driven by volume increases across all product categories.
- Profitability: Net earnings rose 17.1% to $346.2 million. Operating income increased 17.7% despite a $32.7 million impairment charge.
- Margin Compression: Gross margin decreased to 73.6% from 75.1%, primarily due to $24.0 million in impairment losses recorded in Cost of Goods Sold.
- Share Repurchases: The company spent $503.2 million on treasury share acquisitions in Q1 2007, compared to $64.0 million in Q1 2006.
- Segment Performance:
- United States: Sales up 10.0%; Operating income up 19.7%.
- International: Sales up 18.6% (14.0% constant currency); Operating income up 23.6%.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items and Impairments
The company recognized $32.7 million in impairment losses related to refractive product assets and inventory valuation. This included $24.0 million in Cost of Goods Sold and $8.7 million in amortization of intangibles. This charge was driven by a review of the refractive product line following a Device Safety Alert.
Product Safety and Regulatory Risks
- CustomCornea/LADAR6000: On February 21, 2007, Alcon issued a Device Safety Alert directing physicians to discontinue CustomCornea wavefront system myopia procedures using the LADAR6000 excimer laser due to reports of decreased visual acuity. Refractive sales decreased 13.0% in Q1 2007. Future technology fee revenue is expected to be reduced.
- Patent Litigation: Active infringement suits against generic manufacturers Teva (Vigamox) and Apotex (Patanol). FDA approval for generics is delayed for 30 months pending litigation resolution, but potential competition remains a risk to future sales.
Capital Allocation and Dividends
- Dividend Proposal: The Board proposed a dividend of CHF 2.50 per share (approx. $2.03), totaling an estimated $604 million, subject to shareholder approval at the May 9, 2007 meeting.
- Share Cancellation: Shareholders will vote on a proposal to cancel approximately 8 million treasury shares.
Accounting Changes
Effective January 1, 2007, the company adopted FIN No. 48 (Accounting for Uncertainty in Income Taxes), resulting in a $30.0 million decrease in tax liabilities and a corresponding increase in retained earnings.
Investor Verification Checklist
- Refractive Segment Outlook: Verify the long-term impact of the LADAR6000 safety alert on refractive sales and technology fees.
- Dividend Approval: Confirm shareholder approval of the proposed $604 million dividend at the May 9, 2007 meeting.
- Patent Litigation Status: Monitor the 30-month stay periods for Teva (Vigamox) and Apotex (Patanol) generic challenges.
- Tax Position: Review the impact of the ongoing IRS examination (2003-2005) and the Swiss-U.S. Advance Pricing Agreement (APA) negotiations on future tax reserves.
- Share Buyback Execution: Track the execution of the remaining authorized share repurchases and the proposed cancellation of 8 million shares.